Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Ultra bad cholesterol

Bad cholesterol, known as LDL is known to be sticky but this ultra –bad called MGmin-LDL is found to be stickier meaning it's more likely to attach to arterial walls. This is more dangerous because when LDL attaches to artery walls it forms fatty plaques that cause coronary heart disease (CHD). As fatty plaques grow, they narrow the arteries and reduce blood flow and also may trigger a stroke or heart attack. CHD is the most common type of heart disease and kills almost 450,000 Americans each year.

29 May 2011

High blood pressure becoming more common in young adults: Study

According to a new study about one in five young adults may have high blood pressure. The researchers from the University of North Carolina at Chapel Hill analyzed blood pressure data from the National Longitudinal Study of Adolescent Health, called Add Health, and compared it with data from the National Health and Nutrition Examination Survey, commonly referred to as NHANES. They focused specifically on the information about adults age 24 to 32.

29 May 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), disclosed results from an interim analysis of the AIM-HIGH clinical trial.

27 May 2011

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.

27 May 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

Gout drug success for Novartis

Novartis AG's new gout therapy drug gives patients better pain relief and significantly cuts the risk of new attacks say two late stage studies. The studies show that more than 450 patients taking Ilaris, or ACZ885, had less pain and the risk of new attacks were reduced by up to 68 percent compared to those taking an injectable steroid to treat gouty arthritis attacks, which can last for a week or more.

26 May 2011

Study links decrease in U.S. workplace physical activity with obesity epidemic

In a new study conducted at the Pennington Biomedical Research Center, scientists have found that the decrease in workplace physical activity over the past fifty years is a significant contributor to the obesity epidemic.

26 May 2011

New Hypertension Management Program study results revealed at ASH scientific meeting

High blood pressure - the silent killer - is taking a hit from a new, ground-breaking treatment program from the Heart and Stroke Foundation of Ontario.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

25 May 2011

Obesity and diabetes rates continue to rise despite decline in consumption of sweeteners

A comprehensive review of research focusing on the debate between High Fructose Corn Syrup and other sweeteners presented today finds there is no evidence of any significant variation in the way the human body metabolizes HFCS as opposed to standard table sugar, or any difference in impact on risk factors for chronic disease.

25 May 2011

Baked, broiled fish consumption linked to reduced heart failure risk in postmenopausal women

The risk of developing heart failure was lower for postmenopausal women who frequently ate baked or broiled fish, but higher for those who ate more fried fish, in a study reported in Circulation: Heart Failure, an American Heart Association journal.

25 May 2011

Vectra DA blood test may help predict patients' response to rheumatoid arthritis therapy

Crescendo Bioscience- today announced data indicating that Vectra- DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy.

25 May 2011

Brisk walking may delay or even prevent progression of prostate cancer in men

Men with prostate cancer can improve their outcomes if they walk briskly for at least three hours a week following their diagnosis, according to a recent study in Cancer Research, a journal of the American Association for Cancer Research.

25 May 2011

HDL to acquire Harris Scientific

Health Diagnostic Laboratory Inc., a CAP accredited leader in health management, announced today that it will expand its comprehensive test menu of risk factors and biomarkers for cardiovascular and related diseases through the acquisition of Harris Scientific, Inc., a company providing omega-3 fatty acid testing based on the research of Dr. William Harris.

25 May 2011

Studies consistently confirm health benefits of fruit consumption

What do apples, blueberries and prunes have in common? If you guessed that they are all fruits you would be correct. However, that would only be scratching the surface. The fact is that studies consistently confirm the benefits of eating a variety of fruit daily. These benefits include better blood profiles, increased bone density and a strong defense against obesity.

24 May 2011

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Takeda Global Research & Development Center, Inc. U.S., today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone.

24 May 2011

Circulation journal introduces new series on preventive cardiology, lifestyle interventions

Today, Circulation: Journal of the American Heart Association launches a year-long themed series that will focus on the prevention of cardiovascular disease.

24 May 2011

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Ultra bad cholesterol

High blood pressure becoming more common in young adults: Study

Efficacy of Abbott cholesterol drug in question

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

Gout drug success for Novartis

Study links decrease in U.S. workplace physical activity with obesity epidemic

New Hypertension Management Program study results revealed at ASH scientific meeting

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

Obesity and diabetes rates continue to rise despite decline in consumption of sweeteners

Baked, broiled fish consumption linked to reduced heart failure risk in postmenopausal women

Vectra DA blood test may help predict patients' response to rheumatoid arthritis therapy

Brisk walking may delay or even prevent progression of prostate cancer in men

HDL to acquire Harris Scientific

Studies consistently confirm health benefits of fruit consumption

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Circulation journal introduces new series on preventive cardiology, lifestyle interventions

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in